Comparative Pharmacology
Head-to-head clinical analysis: NEOBIOTIC versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOBIOTIC versus VIBATIV.
NEOBIOTIC vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
1 g intravenously every 12 hours.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic